Salute e Benessere

Wobble Genomics Presents Latest Data at ESMO: establishing the robustness of an…

The method identified novel isoforms of key cancer genes HER2 and TROP2 in patient blood samples, allowing more effective ADC development and more accurate patient stratification. The method identified novel isoforms of key cancer genes HER2 and TROP2 in patient blood samples, allowing more effective ADC development and more accurate patient stratification. Dr.Richard Kuo, Wobble Genomics CEO and Founder, said: "Our new platforms mark a major breakthrough in liquid biopsy technology,...
PR Newswire
17/10/2025

Sterile Dry Powder Active Pharmaceutical Ingredient (API) Market is expected to…

The global Sterile Dry Powder API Market is expanding due to the growing demand for aseptic pharmaceutical production and biologics. With major players investing in sterile manufacturing facilities, the market is set to see strong growth across key regions like North America, Europe, and Asia-Pacific. The global Sterile Dry Powder API Market is expanding due to the growing demand for aseptic pharmaceutical production and biologics. With major players investing in sterile manufacturing...
PR Newswire
17/10/2025

POP Treatment and Management / Pelvic Organ Prolapse Market worth $1.06 billion…

Browse in-depth TOC on "POP Treatment and Management / Pelvic Organ Prolapse Market" Browse in-depth TOC on "POP Treatment and Management / Pelvic Organ Prolapse Market" 345 - Tables 42 - Figures 331 - Pages By treatment,The POP Treatment and Management / Pelvic Organ Prolapse market is divided into two main segments based on treatment: surgical and non-surgical. Surgical treatment type is further divided into colpocleisis, colporrhapy, sacrocolpopexy, sacrohysteropexy…
PR Newswire
17/10/2025

Syngene International invests in dedicated peptide laboratory and advanced…

The dedicated peptide laboratory is designed to produce a wide range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates, and supports synthesis scale-up to 800 mmol (millimole). With six automated peptide synthesizers operating in parallel and equipped with robotic arms, the lab reduces project timelines by weeks or even months while ensuring consistent results. It also features integrated Solid-Phase Peptide Synthesis (SPPS), High-Performance Liquid…
PR Newswire
17/10/2025

Boehringer’s zongertinib demonstrated a 77% objective response rate in…

/ Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 ( ERBB2 )-mutant NSCLC were presented for the first time at ESMO 2025. Confirmed response by blinded independent central review was 77%, with 96% of patients achieving disease control. 1 Zongertinib recently received Breakthrough Therapy Designations for first-line treatment by the U.S. FDA and China’s CDE. Boehringer Ingelheim reported...
Nasdaq GlobeNewswire
17/10/2025

Patient Experience Technology Market worth $1.16 billion by 2030 with 11.8% CAGR…

Browse in-depth TOC on "Patient Experience Technology Market" Browse in-depth TOC on "Patient Experience Technology Market" 150 - Tables 50 - Figures 350 - Pages By offerings,the patient experience technology market is segmented into software and services. The software segment is expected to dominate the patient experience technology market during the forecast period. The growth is driven by the increasing adoption of digital tools that enhance patient engagement and...
PR Newswire
17/10/2025

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – MIT and Harvardscientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving…
PR Newswire
17/10/2025

Precision Oncology Approaches Drive $312B Market Transformation

VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates across oncology as companies advance novel mechanisms targeting previously difficult populations, with recent clinical data demonstrating high response rates in molecularly defined patient subgroups while FDA priority reviews compress development timelines for innovative platforms1. Multi-cancer early detection blood tests have correctly identify two thirds of cancers with a…
PR Newswire
17/10/2025

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed…

75% Objective Response Rate as 12 out of 16 advanced melanoma patients had objective clinical responses, with 11 of the 12 responders continuing to respond at 24 months follow-upImmune activation observed in all patients with 81% of EVX-01’s vaccine targets triggering a specific responseTreatment was well toleratedData is presented today at the ESMO Congress and will be discussed at a webinar with key opinion leader Professor Muhammad Adnan Khattak on October 22, 2025...
Nasdaq GlobeNewswire
17/10/2025

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of…

After 5 years, Kisqali ®plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival 1 Kisqali remains the only CDK4/6 inhibitor demonstrating consistent and clinically meaningful benefit across the broadest population of HR+/HER2- early breast cancer (EBC) patients, including those with node-negative disease 1 Data also show a 29.1% risk reduction in distant disease-free survival, and a positive trend in...
Nasdaq GlobeNewswire
17/10/2025

Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat…

Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopeniaRecommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant improvements in bleeding, quality of life measures, and other ITP symptoms If approved, Wayrilz will be the first BTK inhibitor for ITP in the EU, targeting the root cause of the disease through multi-immune modulation Paris, October 17, 2025.The European Medicines Agency’s...
Nasdaq GlobeNewswire
17/10/2025

Press Release: Sanofi provides update on regulatory review in the EU for…

Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host diseaseParis, October 17, 2025.The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the marketing authorisation application for Rezurock (belumosudil) for the third-line treatment of adults and pediatric patients with chronic graft-versus-host disease (cGVHD). Sanofi will seek a re-examination of the CHMP opinion.cGVHD is a...
Nasdaq GlobeNewswire
17/10/2025

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults…

If approved, Scemblix will be indicated for adults with chronic myeloid leukemia (CML), both newly diagnosed and previously treated, expanding access to four times as many patients in EuropeScemblix is the only CML treatment with a superior efficacy and favorable safety and tolerability profile versus available first-line treatments 1 ,2 Despite available first-line treatments, 50% of patients newly diagnosed with CML miss treatment goals within one year, many of whom...
Nasdaq GlobeNewswire
17/10/2025

CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis

Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone 1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study 2 Lupus nephritis is a debilitating condition that severely impacts a person’s quality of life and affects more than 1.7 million people worldwide 3,4 Basel, 17 October, 2025 - Roche (SIX:...
Nasdaq GlobeNewswire
17/10/2025

RoboUP Pre-Launches Raccoon 2 SE on Kickstarter -- A Smart Robot Mower at the…

Founded in 2016, RoboUP has been dedicated in creating smarter, greener, and more connected living spaces. After years of helping medium and large lawn owners simplify their routines, the team realized small garden owners face their own challenges. Busy lifestyles leave little time for lawn care, and most robot mowers on the market are oversized and overpriced for small yards, making them stick to mowing by hand. For elderly homeowners, manual mowing can also be tiring and unsafe, turning a…
PR Newswire
17/10/2025

Adhesion Barrier Market 2025-30 Outlook Shows 7.5% CAGR as North America Leads…

North America leads, supported by widespread minimally invasive surgeries, hospital protocols, and reimbursement incentives that favor reduced post-surgical complications. Europe grows steadily with value-based care initiatives and multifunctional barrier adoption. Asia-Pacific is the fastest-growing region, driven by hospital modernization, rising surgical volumes, and expanding national reimbursement programs. Growth in the Middle East & Africa and Latin America is moderate, fueled by…
PR Newswire
17/10/2025

AKYNZEO® demonstrates superior prevention of chemotherapy-induced nausea and…

AKYNZEO ® demonstrates superior prevention of chemotherapy-induced nausea and vomiting compared to the standard of care in patients receiving moderately emetogenic chemotherapy with additional predictive factors Results from the MyRisk clinical trial, accepted for publication in the Annals of Oncology, will be presented today at ESMO 2025 as an oral presentationLugano, Switzerland, October 17, 2025– Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record...
Nasdaq GlobeNewswire
17/10/2025

Duchenne Muscular Dystrophy Therapeutics Market Surges Toward $6.6B by 2033 as…

Browse in-depth TOC on "Duchenne Muscular Dystrophy Therapeutics Market" Browse in-depth TOC on "Duchenne Muscular Dystrophy Therapeutics Market" 70 – Tables 66 – Figures 195 – Pages Therapeutic Landscape: Molecular Therapies Redefine the Standard The market's segmentation reveals a powerful trend toward precision medicine. In 2024,Molecular-Based Therapiesdominated the landscape with45.1% market share, translating to approximatelyUS$988 million in global revenue...
PR Newswire
17/10/2025

Smartee Expands European Footprint with Invisible Mandibular Repositioning…

Clinical Recognition: GS Technology in Austrian Practice Clinical Recognition: GS Technology in Austrian Practice One of the highlights of the congress was a keynote lecture byDr.Thomas Felkai , a respected orthodontist and one ofAustria'searly adopters of Smartee GS mandibular Repositioning Technology. Drawing from his clinical experience, Dr. Felkai shared how this innovative protocol provides a new approach to malocclusion treatment by advancing mandible at the first phase of...
PR Newswire
17/10/2025

MVZ HPH Brings ctDNA Blood Test for Cancer Monitoring to Europe, Based on…

HPH MRD testing will be performed in the company's laboratories in Hamburg, Germany, providing clinicians with potential access to next-generation MRD testing. Local availability will help ensure improved clinical implementation and timely delivery of results. All testing and data will remain with HPH in Germany, facilitating compliance with data protection and regulatory standards while supporting access. The HPH MRD test leverages whole-genome sequencing to analyze a patient's tumor tissue and…
PR Newswire
17/10/2025

AB Science announces the successful completion of a EUR 2.8 million private…

PRESS RELEASEAB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.8 MILLION PRIVATE PLACEMENTAB SCIENCE IS FULLY FINANCED TO FINISH PHASE 1 OF AB8939 IN AML AND TO EXECUTE AN EXPANSION PHASE TO MAXIMIZE CHANCE OF SUCCESS OF FUTURE REGISTRATION STUDYParis, October 17, 2025, 8am AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed...
Nasdaq GlobeNewswire
17/10/2025

Levoit to Showcase Advanced Air Purification Solutions at KSA Baby Expo 2025

This expo debut highlights Levoit's commitment to the Saudi market, where indoor air quality is a paramount concern for parents. Featuring advanced HEPA filtration and smart sensors, Levoit products provide peace of mind by ensuring the air at home is clean and safe. This expo debut highlights Levoit's commitment to the Saudi market, where indoor air quality is a paramount concern for parents. Featuring advanced HEPA filtration and smart sensors, Levoit products provide peace of mind by...
PR Newswire
17/10/2025

Klea Holding confirms its hypergrowth in the Q3 2025 and its annual targets

Number of tests performed increased by +35% in Q3 and by +48% at the end of the 9M of the financial year. New revenue record in September 2025 in the Health & Wellness segment. Work resumes on the opening of the first Smart Health digital medical centre in Saudi Arabia. Confirmation of objectives: significant improvement in EBITDA, reduction of the…
Actusnews Wire
17/10/2025

AMFRESH Group Acquires 100% of TERRAMARA FRESH in Mexico, Strengthening Its…

Advanced Genetics and Farming driving the Next Generation of Table Grapes, Blueberries, and Cherries This milestone reflects the natural evolution of both organizations and their aligned strategic vision, celebrating a partnership built on trust, innovation, and a shared purpose to deliver high-quality varietal offerings to retail partners.With over 600 hectares of premium farming investment across two major production areas in Mexico, the acquisition strengthens AMFRESH’s Pacific Rim...
Nasdaq GlobeNewswire
17/10/2025
Altri  Comunicati